{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:30:19Z","timestamp":1790206219801,"version":"4.1.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["research grant paid to Sorbonne University"],"award-info":[{"award-number":["research grant paid to Sorbonne University"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0226924","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T18:27:47Z","timestamp":1579804067000},"page":"e0226924","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells"],"prefix":"10.1371","volume":"15","author":[{"given":"Martine","family":"Auclair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Gu\u00e9nantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Fellahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-4186","authenticated-orcid":true,"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,23]]},"reference":[{"issue":"16","key":"pone.0226924.ref001","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/QAD.0000000000000807","article-title":"Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients","volume":"29","author":"P Duffau","year":"2015","journal-title":"AIDS"},{"key":"pone.0226924.ref002","article-title":"Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients","author":"JP Bastard","year":"2019","journal-title":"Diabetes Metab"},{"issue":"12","key":"pone.0226924.ref003","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/cid\/ciu701","article-title":"Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study","volume":"59","author":"J Schouten","year":"2014","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"9","key":"pone.0226924.ref004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment","volume":"18","author":"C Lagathu","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"17","key":"pone.0226924.ref005","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","author":"DADS Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"pone.0226924.ref006","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1093\/infdis\/jiw288","article-title":"Cardiovascular Disease, Statins, and HIV","volume":"214","author":"AR Eckard","year":"2016","journal-title":"The Journal of infectious diseases"},{"issue":"5","key":"pone.0226924.ref007","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2012.06.063","article-title":"HIV and coronary heart disease: time for a better understanding","volume":"61","author":"F Boccara","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"pone.0226924.ref008","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archinternmed.2010.197","article-title":"Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4","volume":"170","author":"S Lang","year":"2010","journal-title":"Arch Intern Med"},{"issue":"6","key":"pone.0226924.ref009","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","article-title":"Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study","volume":"5","author":"L Ryom","year":"2018","journal-title":"Lancet HIV"},{"issue":"4","key":"pone.0226924.ref010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4292\/wjgpt.v7.i4.469","article-title":"Bilirubin in coronary artery disease: Cytotoxic or protective","volume":"7","author":"N Gupta","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"18","key":"pone.0226924.ref011","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1097\/QAD.0000000000001676","article-title":"Limiting cardiovascular events associated with HIV and antiretroviral therapy","volume":"31","author":"BG Brenner","year":"2017","journal-title":"AIDS"},{"issue":"9","key":"pone.0226924.ref012","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study","volume":"74","author":"C Katlama","year":"2019","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"S8","key":"pone.0226924.ref013","first-page":"e25187","article-title":"48-week changes in biomarkers in subjects with high cardiovascular risk boosted switching from ritonavir-protease inhibitors to dolutegravir: the NEAT022 study","volume":"21","author":"E Martinez","year":"2018","journal-title":"Journal of the International AIDS Society"},{"issue":"4","key":"pone.0226924.ref014","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/cid\/ciy505","article-title":"Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age >\/ = 50 Years: Final 96-Week Results of the NEAT022 Study. Clinical infectious diseases: an official publication of the","volume":"68","author":"JM Gatell","year":"2019","journal-title":"Infectious Diseases Society of America"},{"issue":"2","key":"pone.0226924.ref015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/COH.0000000000000445","article-title":"Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials","volume":"13","author":"AM Hill","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"pone.0226924.ref016","article-title":"LOWER CARDIOVASCULAR DISEASE RISK ASSOCIATED WITH INTEGRASE INHIBITORS","author":"JA O'Halloran","year":"2019","journal-title":"CROI"},{"issue":"9","key":"pone.0226924.ref017","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV","volume":"381","author":"WDF Venter","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0226924.ref018","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2055-6640(20)30277-6","article-title":"Are new antiretroviral treatments increasing the risks of clinical obesity?","volume":"5","author":"A Hill","year":"2019","journal-title":"J Virus Erad"},{"key":"pone.0226924.ref019","article-title":"GREATER WEIGHT GAIN AMONG TREATMENT-NAIVE PERSONS STARTING INTEGRASE INHIBITORS","author":"K Bourgi","year":"2019","journal-title":"CROI"},{"key":"pone.0226924.ref020","article-title":"RISK FACTORS FOR EXCESS WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR\u2013BASED ART","author":"JE Lake","year":"2019","journal-title":"CROI"},{"key":"pone.0226924.ref021","article-title":"Greater Weight Gain in Treatment Naive Persons Starting Dolutegravir-Based Antiretroviral Therapy","author":"K Bourgi","year":"2019","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"pone.0226924.ref022","first-page":"e0209911","article-title":"Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001\/ANRS143 randomised trial","volume":"14","author":"JI Bernardino","year":"2019","journal-title":"PloS onePubMed Central PMCID"},{"issue":"3","key":"pone.0226924.ref023","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/jac\/dky507","article-title":"Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients","volume":"74","author":"L Calza","year":"2019","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"3","key":"pone.0226924.ref024","doi-asserted-by":"crossref","first-page":"ofw174","DOI":"10.1093\/ofid\/ofw174","article-title":"Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s","volume":"3","author":"S Dirajlal-Fargo","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"pone.0226924.ref025","article-title":"DOLUTEGRAVIR AND INSULIN RESISTANCE","author":"J Lo","year":"2019","journal-title":"CROI"},{"issue":"4","key":"pone.0226924.ref026","doi-asserted-by":"crossref","first-page":"ofz112","DOI":"10.1093\/ofid\/ofz112","article-title":"Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study","volume":"6","author":"D Francisci","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"pone.0226924.ref027","doi-asserted-by":"crossref","first-page":"28853","DOI":"10.1038\/srep28853","article-title":"Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients","volume":"6","author":"S Piconi","year":"2016","journal-title":"Scientific reports"},{"issue":"8","key":"pone.0226924.ref028","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3851\/IMP3160","article-title":"Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence","volume":"22","author":"P Afonso","year":"2017","journal-title":"Antiviral therapy"},{"issue":"12","key":"pone.0226924.ref029","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/BF03401992","article-title":"CXC and CC chemokine receptors on coronary and brain endothelia","volume":"5","author":"O Berger","year":"1999","journal-title":"Mol Med"},{"issue":"3","key":"pone.0226924.ref030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cvr\/cvt333","article-title":"The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro","volume":"101","author":"JJ Maguire","year":"2014","journal-title":"Cardiovascular research"},{"issue":"8","key":"pone.0226924.ref031","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3851\/IMP2752","article-title":"Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin","volume":"19","author":"M Auclair","year":"2014","journal-title":"Antiviral therapy"},{"issue":"12","key":"pone.0226924.ref032","doi-asserted-by":"crossref","first-page":"H1754","DOI":"10.1152\/ajpheart.00377.2014","article-title":"The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice","volume":"307","author":"LB Gano","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"pone.0226924.ref033","first-page":"2876","article-title":"SRT1720, a SIRT1 specific activator, protected H2O2-induced senescent endothelium","volume":"8","author":"RL Li","year":"2016","journal-title":"Am J Transl Res"},{"issue":"4","key":"pone.0226924.ref034","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2014-01-550285","article-title":"Reduced thrombosis in Klkb1-\/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor","volume":"125","author":"EX Stavrou","year":"2015","journal-title":"Blood"},{"issue":"1\u20133","key":"pone.0226924.ref035","first-page":"68","article-title":"Splitomicin inhibits fMLP-induced superoxide anion production in human neutrophils by activate cAMP\/PKA signaling inhibition of ERK pathway","volume":"688","author":"FC Liu","year":"2012","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"pone.0226924.ref036","doi-asserted-by":"crossref","first-page":"H39","DOI":"10.1152\/ajpheart.00490.2015","article-title":"Endothelial PPAR-gamma provides vascular protection from IL-1beta-induced oxidative stress","volume":"310","author":"M Mukohda","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"pone.0226924.ref037","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.diabet.2014.11.001","article-title":"Ten-year improvement of insulin resistance and growth with recombinant human insulin-like growth factor 1 in a patient with insulin receptor mutations resulting in leprechaunism","volume":"41","author":"M de Kerdanet","year":"2015","journal-title":"Diabetes Metab"},{"issue":"9","key":"pone.0226924.ref038","first-page":"3197","article-title":"Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I","volume":"84","author":"M Auclair","year":"1999","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"6","key":"pone.0226924.ref039","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/hep.29375","article-title":"USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity","volume":"66","author":"S An","year":"2017","journal-title":"Hepatology"},{"issue":"8","key":"pone.0226924.ref040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.20122327","article-title":"USP18 inhibits NF-kappaB and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex","volume":"210","author":"X Liu","year":"2013","journal-title":"J Exp Med"},{"key":"pone.0226924.ref041","doi-asserted-by":"crossref","first-page":"12738","DOI":"10.1038\/srep12738","article-title":"USP18 negatively regulates NF-kappaB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms","volume":"5","author":"Z Yang","year":"2015","journal-title":"Scientific reports"},{"issue":"12","key":"pone.0226924.ref042","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrneph.2016.145","article-title":"The impact of insulin resistance on the kidney and vasculature","volume":"12","author":"F Artunc","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"pone.0226924.ref043","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1002\/jcp.27508","article-title":"Exercise ameliorates insulin resistance via regulating TGFbeta-activated kinase 1 (TAK1)-mediated insulin signaling in liver of high-fat diet-induced obese rats","volume":"234","author":"Y Zhang","year":"2019","journal-title":"J Cell Physiol"},{"issue":"18","key":"pone.0226924.ref044","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/QAD.0b013e328359f29c","article-title":"Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir","volume":"26","author":"E Martinez","year":"2012","journal-title":"AIDS"},{"issue":"14","key":"pone.0226924.ref045","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/01.aids.0000244200.11006.55","article-title":"Effects of atazanavir\/ritonavir and lopinavir\/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","volume":"20","author":"MA Noor","year":"2006","journal-title":"AIDS"},{"key":"pone.0226924.ref046","article-title":"Switch to dolutegravir (DTG) from a boosted protease inhibitor (PI\/r) associated with significant weight gain over 48 weeks in NEAT-022, a randomised 96-week trila","author":"L Waters","year":"2018","journal-title":"HIV Drug Therapy"},{"issue":"7","key":"pone.0226924.ref047","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/ciw017","article-title":"Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s","volume":"62","author":"GA McComsey","year":"2016","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"pone.0226924.ref048","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"HJ Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"issue":"6","key":"pone.0226924.ref049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11904-017-0368-6","article-title":"The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection","volume":"14","author":"JE Lake","year":"2017","journal-title":"Current HIV\/AIDS reports"},{"issue":"5","key":"pone.0226924.ref050","doi-asserted-by":"crossref","first-page":"e0196395","DOI":"10.1371\/journal.pone.0196395","article-title":"Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI\/NNRTI-based antiretroviral therapy","volume":"13","author":"O Offor","year":"2018","journal-title":"PloS one"},{"issue":"Pt B","key":"pone.0226924.ref051","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.yjmcc.2015.01.021","article-title":"Cellular and molecular biology of aging endothelial cells","volume":"89","author":"AJ Donato","year":"2015","journal-title":"J Mol Cell Cardiol"},{"issue":"9","key":"pone.0226924.ref052","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.111.246488","article-title":"FOXOs and sirtuins in vascular growth, maintenance, and aging","volume":"110","author":"MF Oellerich","year":"2012","journal-title":"Circ Res"},{"key":"pone.0226924.ref053","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.yjmcc.2014.12.023","article-title":"Sirtuin function in aging heart and vessels","volume":"83","author":"C Cencioni","year":"2015","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"pone.0226924.ref054","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180250","article-title":"USP18\u2014a multifunctional component in the interferon response","volume":"38","author":"A Basters","year":"2018","journal-title":"Biosci Rep"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T15:02:12Z","timestamp":1614092532000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226924"}},"subtitle":[],"editor":[{"given":"Chiara","family":"Bolego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0226924","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,23]]}}}